Search Result

Results for "

osteosarcoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (11) Autophagy (3) CDK (5) Cholinesterase (ChE) (1) COX (3) Cytochrome P450 (2) DNA/RNA Synthesis (1) DYRK (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (5) Fungal (1) G-quadruplex (1) Histone Acetyltransferase (1) IGF-1R (2) IKK (1) Isotope-Labeled Compounds (1) LIM Kinase (LIMK) (1) MDM-2/p53 (3) Mitophagy (2) MMP (2) NF-κB (2) NOD-like Receptor (NLR) (3) PAI-1 (1) PD-1/PD-L1 (1) PDGFR (1) PI3K (1) RANKL/RANK (4) SARS-CoV (1) Telomerase (1) Toll-like Receptor (TLR) (4) Topoisomerase (1) Tyrosinase (1) VD/VDR (1) VEGFR (1) Wnt (4) β-catenin (5)
By Research Areas:	Cancer (54) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (17) Metabolic Disease (6) Neurological Disease (1)

By Targets:

Akt (2)

Apoptosis (11)

Autophagy (3)

CDK (5)

Cholinesterase (ChE) (1)

COX (3)

Cytochrome P450 (2)

DNA/RNA Synthesis (1)

DYRK (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (5)

Fungal (1)

G-quadruplex (1)

Histone Acetyltransferase (1)

IGF-1R (2)

IKK (1)

Isotope-Labeled Compounds (1)

LIM Kinase (LIMK) (1)

MDM-2/p53 (3)

Mitophagy (2)

MMP (2)

NF-κB (2)

NOD-like Receptor (NLR) (3)

PAI-1 (1)

PD-1/PD-L1 (1)

PDGFR (1)

PI3K (1)

RANKL/RANK (4)

SARS-CoV (1)

Telomerase (1)

Toll-like Receptor (TLR) (4)

Topoisomerase (1)

Tyrosinase (1)

VD/VDR (1)

VEGFR (1)

Wnt (4)

β-catenin (5)

By Research Areas:

Cancer (54)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (17)

Metabolic Disease (6)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0819

Raddeanin A 1 Publications Verification	Apoptosis	Cancer
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway .

HY-B0012

Pamidronic acid 1 Publications Verification	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-122714

SK-216	PAI-1	Cancer
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma .

HY-115995

Antitumor agent-50	Others	Cancer
Antitumor agent-50 (compound 1a), a thiazolidinone, is a potent antitumor agent. Antitumor agent-50 has the potential for osteosarcoma (OS) research .

HY-12579

RO 2468	MDM-2/p53	Cancer
RO 2468 is a potent, orally active and selective p53-MDM2 inhibitor. RO 2468 has anti-proliferative active. RO 2468 suppresses c growth in SJSA1 osteosarcoma models without obvious toxicity .

HY-N8498

GKK1032B	Apoptosis	Cancer
GKK1032B is an alkaloid compound that can be found in endophytic fungus Penicillium sp. GKK1032B can induce the apoptosis of human osteosarcoma MG63 cells through caspase pathway activation .

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P3731

Cdk2/Cyclin Inhibitory Peptide II	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-162121

Antitumor agent-129	Others	Cancer
Antitumor agent-129 (Compound 68) is a thiazolidin-4-one sulfone derivative and an Osteosarcoma (OS) inhibitor with an IC₅₀ value of 0.217 μM, a half-life of 73.8 min (mouse liver microsome) and an excellent pharmacokinetic profile (in vivo bioavailability F = 115%, intraperitoneal administration). Antitumor agent-129 is a potential candidate for OS research .

HY-B0012B

Pamidronic acid sodium	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-B0012A

Pamidronate disodium 1 Publications Verification CGP 23339A	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronate disodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-N7385

Nudol	MMP Apoptosis	Cancer
Nudol is a phenanthrene compound that has anti-cancer activity. Nudol inhibits cell proliferation, induces cell apoptosis. Nudol inhibits MMP-2M and MMP-9 activity (K_i: 988.9 nM, 1.76 μM, respectively). Nudol can be used in the research of cancers, such as osteosarcoma .

HY-145441

GEM–IB	Others	Cancer
GEM–IB is the conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB). GEM–IB as a single agent or in combination with Docetaxel (DTX) demonstrates reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of osteosarcoma (OS) .

HY-115996

Antitumor agent-51	Others	Cancer
Antitumor agent-51 possesses potent and selective inhibitory for osteosarcoma cell growth and migration with IC₅₀ of 21.9 nM in MNNG/HOS cells. Antitumor agent-51 has a considerable bioavailability and a low toxicity .

HY-B0012AR

Pamidronate disodium (Standard)	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronate disodium (Standard) is the analytical standard of Pamidronate disodium.Pamidronate disodium (Standard), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium (Standard) significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium (Standard) can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .

HY-N7135

Tropolone	Tyrosinase Fungal	Metabolic Disease Inflammation/Immunology Cancer
Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC₅₀ value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU ²⁺ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .

HY-N6611

Chimaphilin	IGF-1R	Infection Inflammation/Immunology Cancer
Chimaphilin is an IGF-1R inhibitor (IC₅₀: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola .

HY-169296

IMPDH2-IN-4	VEGFR CDK	Cancer
IMPDH2-IN-4 (compound 2d), a Mycophenolic acid (HY-B0421) analogue, is a selective IMPDH2 inhibitor with a K_i of 1.8 μM. IMPDH2-IN-4 exhibits good cytotoxic activity against osteosarcoma cancer cell lines. IMPDH2-IN-4 possesses a high affinity for VEGFR-2, CDK2, and IMPDH .

HY-13682

Mifamurtide 1 Publications Verification MTP-PE; L-MTP-PE; CGP 19835	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research .

HY-13682B

Mifamurtide sodium 1 Publications Verification MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research .

HY-144653

PDGFR-IN-1	PDGFR Apoptosis	Cancer
PDGFR-IN-1 (compound 7m) is a potent and orally active PDGFR (platelet-derived growth factor receptor) inhibitor, with IC₅₀ values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma .

HY-13682C

Mifamurtide TFA 1 Publications Verification MTP-PE TFA; L-MTP-PE TFA; CGP 19835 TFA	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide TFA has potential for use in rare disease and osteosarcoma research .

HY-134901

WM-3835 2 Publications Verification	Histone Acetyltransferase Apoptosis	Cancer
WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice .

HY-162970

XD23	Others	Cancer
XD23 is a potent osteosarcoma inhibitor that works by downregulating DKK1 and activating the WNT/β-catenin signaling pathway.

HY-32341

Seocalcitol 2 Publications Verification EB 1089	VD/VDR	Cancer
Seocalcitol is a vitamin D analog, binds vitamin D receptor protein from human osteosarcoma MG-63 cells with K_d of 0.27 nM.

HY-124144

MMV667492	Endogenous Metabolite	Cancer
MMV667492 is a potent Ezrin inhibitor with the activity to inhibit the invasion phenotype of osteosarcoma cells. MMV667492 exhibited potent anti-Ezrin activity in all biological assays and its compound properties were superior to NSC305787. MMV667492 was able to exhibit morphological defect phenotypes associated with Ezrin inhibition in zebrafish embryos. MMV667492 also showed the ability to inhibit the lung metastasis of osteosarcoma cells that highly expressed Ezrin .

HY-157126

Pterostilbene-isothiocyanate PTER-ITC	β-catenin	Cancer
Pterostilbene-isothiocyanate (PTER-ITC) exhibits potent anticancereffects in vitro. Pterostilbene-isothiocyanate against human osteosarcoma cells by abrogating the β-catenin/TCF-4 interaction .

HY-161417

LIMK-IN-2	LIM Kinase (LIMK)	Cancer
LIMK-IN-2 (Compound 52) is an LIMK inhibitor. LIMK-IN-2 can suppress the cell migration of osteosarcoma and cervical cancer cells, demonstrating potential anti-angiogenic activity .

HY-169053

SU1261	IKK NF-κB	Cancer
SU1261 is an IKK inhibitor with K_i values of 10 nM and 680 nM for IKKα and IKKβ, respectively. SU1261 can inhibit non-canonical NF-κB signaling in U2OS osteosarcoma cells .

HY-138969

(±)10(11)-EDP ethanolamide 10,11-EDP-EA; 10,11-EDP epoxide; 10,11-Epoxy docosapentaenoic ethanolamide	Others	Others
(±)10(11)-EDP ethanolamide (10,11-EDP-EA) (compound C) is an ω-3 endocannabinoid epoxide derivative with antiangiogenic, antitumor and anti-migratory properties in osteosarcoma models.

HY-158318

NUDT5/14 antagonist 1	DNA/RNA Synthesis	Cancer
NUDT5/14 antagonist 1 (Compound 9) is a selective, dual antagonist for nucleotide diphosphate kinase NUDT5 and NUDT14, with IC₅₀ of 0.27 and 0.16 μM, respectively. NUDT5/14 antagonist 1 binds to Bruton’s tyrosine kinase (BTK) with an IC₅₀ of 0.377 μM .

HY-13682A

Mifamurtide sodium hydrate MTP-PE sodium hydrate; L-MTP-PE sodium hydrate; CGP 19835 sodium hydrate	Others	Inflammation/Immunology Cancer
Mifamurtide (sodium hydrate) (MTP-PE (sodium hydrate); L-MTP-PE (sodium hydrate); CGP 19835 (sodium hydrate)) is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research .

HY-B1508

Vitamin K4 Acetomenaphthone	Endogenous Metabolite Apoptosis	Cardiovascular Disease Cancer
Vitamin K4 is a chemically synthesized Vitamin K which plays an important role in the normal blood coagulation system. Vitamin K4 arrests the cells in S phase and induces apoptosis. Vitamin K4 can be used for the research of cancer, such as prostate cancer and osteosarcoma .

HY-N2112

Glaucocalyxin A 2 Publications Verification	PI3K Akt Apoptosis	Cancer
Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect .

HY-12941

AM-7209	MDM-2/p53	Cancer
AM-7209 is a potent and selective MDM2-p53 interaction inhibitor with a K_d of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC₅₀ of 1.6 nM. AM-7209 shows antitumor activities .

HY-163518

Antitumor agent-153	E1/E2/E3 Enzyme	Cancer
Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity .

HY-123369

BMI-1026	CDK Apoptosis	Cancer
BMI-1026 is a cyclin-dependent kinase 1 (Cdk1) inhibitor with IC₅₀ of 2.3 nM. BMI-1026 induces apoptosis by arresting the G2-M phase .

HY-N0153

Naringin Maximum Cited Publications 13 Publications Verification Naringoside	Cytochrome P450 Autophagy Mitophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities. Naringin also inhibits proliferation and invasion and induces apoptosis in human osteosarcoma cells by inhibiting zinc finger E-box binding homeobox 1 (Zeb1) .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-N0153R

Naringin (Standard) Naringoside (Standard)	Endogenous Metabolite Cytochrome P450 Mitophagy Autophagy	Inflammation/Immunology Cancer
Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities. Naringin also inhibits proliferation and invasion and induces apoptosis in human osteosarcoma cells by inhibiting zinc finger E-box binding homeobox 1 (Zeb1) .

HY-17372

Rofecoxib 3 Publications Verification MK 966	COX	Inflammation/Immunology Cancer
Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

HY-B1508R

Vitamin K4 (Standard)	Endogenous Metabolite Apoptosis	Cardiovascular Disease Cancer
Vitamin K4 (Standard) is the analytical standard of Vitamin K4. This product is intended for research and analytical applications. Vitamin K4 is a chemically synthesized Vitamin K which plays an important role in the normal blood coagulation system. Vitamin K4 arrests the cells in S phase and induces apoptosis. Vitamin K4 can be used for the research of cancer, such as prostate cancer and osteosarcoma .

HY-107636

DC_AC50 3 Publications Verification	Apoptosis	Cancer
DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance .

HY-161082

Topoisomerase I inhibitor 12	Topoisomerase	Cancer
Topoisomerase I inhibitor 12 (compound 12), a Camptothecin (HY-16560)-based derivative, is a potent Topoisomerase I inhibitor. Topoisomerase I inhibitor 12 shows anticancer activity .

HY-17372R

Rofecoxib (Standard)	COX	Inflammation/Immunology Cancer
Rofecoxib (Standard) is the analytical standard of Rofecoxib. This product is intended for research and analytical applications. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

HY-17372S

Rofecoxib-d5	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Rofecoxib-d₅ is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells)[1][2].

HY-13777C

Zoledronate disodium CGP 42446 disodium; CGP42446A disodium; ZOL 446 disodium	Others	Cancer
Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone turnover and stabilizing the bone matrix. Zoledronate disodium has demonstrated notable effectiveness in managing Paget's disease of bone by suppressing metabolic activity and alleviating bone pain. Zoledronate disodium is being investigated in the ongoing ZiPP trial for its potential to prevent disease progression in patients with Paget's disease. Zoledronate disodium also exhibits diverse anti-tumor effects in osteosarcoma, further highlighting its multifunctional therapeutic applications.

HY-12580

RO5353	MDM-2/p53	Cancer
RO5353 is an orally active inhibitor for p53-MDM2 with an IC₅₀ of 7 nM for MDM2. RO5353 inhibits the proliferation of wild-type p53 cancer cells with an average IC₅₀ of 7 nM. RO5353 exhibits antitumor efficacy and good pharmacokinetic characteristics in mice .

HY-108477

TMPyP4 tosylate 4 Publications Verification TMP 1363	G-quadruplex Telomerase Cholinesterase (ChE) SARS-CoV	Cancer
TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand. TMPyP4 tosylate inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate is a telomerase inhibitor and inhibits cancer cells proliferation. TMPyP4 tosylate is also a stabilizer of nucleic acid secondary structure and an acetylcholinesterase inhibitor. Besides, TMPyP4 tosylate has antiviral activity against SARS-CoV-2 .

Cat. No.	Product Name	Target	Research Area